Featured Research

from universities, journals, and other organizations

Heparan sulfate adjusts functions of growth factor proteins

Date:
May 4, 2011
Source:
Boston University Medical Center
Summary:
When the human genome project produced a map of human genes, the number of genes in humans turned out to be relatively small, approximately the same number as in primitive nematode worms. The difference in complexity between human and primitive organisms results from the ways in which the functions of genes are elaborated, rather from just the number of genes. Researchers are showing how heparan sulfate, a carbohydrate that is expressed on the surface of all human cells, adjusts the functions of growth factor proteins.

When the human genome project produced a map of human genes, the number of genes in humans turned out to be relatively small, approximately the same number as in primitive nematode worms. The difference in complexity between human and primitive organisms results from the ways in which the functions of genes are elaborated, rather from just the number of genes. Boston University School of Medicine (BUSM) researchers are showing how heparan sulfate, a carbohydrate that is expressed on the surface of all human cells, adjusts the functions of growth factor proteins.

These findings currently appear online in the Journal of Biological Chemistry.

Each cell responds to signals in the form of growth factor proteins that bind to cell surfaces. "The heparan sulfate on each cell helps the growth factor proteins connect with a growth factor receptor that is necessary for the signaling to occur," explained Joseph Zaia, PhD, an associate professor of Biochemistry at BUSM. Cells can change the way they respond to growth factors by altering the structure of the heparan sulfate on their surfaces.

Under the direction of Zaia, researchers from BUSM's department of Biochemistry have produced a new picture of the structure of the heparan sulfate and how it interacts with growth factor proteins. These new results demonstrate that growth factors home into regions of the heparan sulfate chains known as non-reducing ends. "Such binding of growth factors to the non-reducing ends of heparan sulfate chains may be a general means whereby normal cell growth is maintained. Conversely, a breakdown in such signaling may contribute to abnormal cell growth," he added.


Story Source:

The above story is based on materials provided by Boston University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. Naimy, J. A. Buczek-Thomas, M. A. Nugent, N. Leymarie, J. Zaia. Highly sulfated non reducing end-derived heparan sulfate domains bind fibroblast growth factor-2 with high affinity and are enriched in biologically active fractions.. Journal of Biological Chemistry, 2011; DOI: 10.1074/jbc.M110.204693

Cite This Page:

Boston University Medical Center. "Heparan sulfate adjusts functions of growth factor proteins." ScienceDaily. ScienceDaily, 4 May 2011. <www.sciencedaily.com/releases/2011/05/110504162008.htm>.
Boston University Medical Center. (2011, May 4). Heparan sulfate adjusts functions of growth factor proteins. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/05/110504162008.htm
Boston University Medical Center. "Heparan sulfate adjusts functions of growth factor proteins." ScienceDaily. www.sciencedaily.com/releases/2011/05/110504162008.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins